Results 21 to 30 of about 11,862,011 (403)

Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Dermatology and Therapy, 2020
The outbreak of the novel coronavirus known as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) causing COVID-19 was first reported in late December 2019.
Nicholas D. Brownstone, Quinn G. Thibodeaux, Vidhatha D. Reddy, Bridget A. Myers, Stephanie Y. Chan, Tina Bhutani, Wilson Liao   +6 more
doaj   +1 more source

The TNF/IL‐23/IL‐17 axis—Head‐to‐head trials comparing different biologics in psoriasis treatment

Scandinavian Journal of Immunology, 2020
Psoriasis is a T cell–mediated disease with autoimmune characteristics modulated by genetic susceptibility along with environmental triggers. Inflammatory pathways marked with excessive production of cytokines IL‐12 and IL‐23, drive differentiation of ...
Lisa Lynn ten Bergen, A. Petrovič, A. K. Aarebrot, S. Appel   +3 more
semanticscholar   +1 more source

Plasma total antioxidant capacity and peroxidation biomarkers in psoriasis [PDF]

, 2016
Systemic biomarkers of oxidative stress can be relevant for assessment of psoriasis severity, for prediction of the outcome of therapy and of the development of comorbidities.
Cavaliere, Arturo, Palmery, Maura, Peluso, Ilaria   +2 more
core   +2 more sources

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)

Frontiers in Medicine, 2023
IntroductionBimekizumab is a monoclonal antibody that targets Interleukin-17 A and F, approved for the treatment of moderate-to-severe plaque psoriasis.
Luigi Gargiulo, Luigi Gargiulo, Alessandra Narcisi, Luciano Ibba, Luciano Ibba, Anna Balato, Luca Bianchi, Pina Brianti, Dario Buononato, Martina Burlando, Giacomo Caldarola, Giacomo Caldarola, Anna Campanati, Elena Campione, Carlo G. Carrera, Andrea Carugno, Andrea Carugno, Antonio Cristaudo, Francesco Cusano, Paolo Dapavo, Annunziata Dattola, Clara De Simone, Clara De Simone, Francesca M. Gaiani, Paolo Gisondi, Alessandro Giunta, Francesco Loconsole, Vincenzo Maione, Edoardo Mortato, Angelo V. Marzano, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Santo R. Mercuri, Annamaria Offidani, Diego Orsini, Aurora Parodi, Giovanni Pellacani, Luca Potestio, Pietro Quaglino, Antonio G. Richetta, Francesca Romano, Paolo Sena, Marina Venturini, Piergiorgio Malagoli, Antonio Costanzo, Antonio Costanzo   +46 more
doaj   +1 more source

Erythrodermic Psoriasis Managed with Risankizumab

Case Reports in Dermatology, 2022
Erythrodermic psoriasis (EP) is a severe, often refractory, variant of psoriasis. Due to the high morbidity and mortality rate associated with EP and other causes of erythroderma, they are often classified as dermatologic emergencies.
Abdulmajeed Alajlan, Abdulaziz Madani, Tala Ammar Qadoumi, Alhanouf Aljaloud, Mohammed Alessa   +4 more
doaj   +1 more source

A Rationally Designed Micellar Nanocarrier for the Delivery of Hydrophilic Methotrexate in Psoriasis Treatment.

ACS Applied Bio Materials, 2020
Methotrexate (MTX) is broadly applied in the clinic for the treatments of cancers and autoimmune diseases. Targeted delivery of MTX is attractive to improve its efficacy and reduce off-target toxicity.
Dandan Guo, Changying Shi, Lili Wang, Xiaotian Ji, Shengle Zhang, Juntao Luo   +5 more
semanticscholar   +1 more source

Viewpoint on handling anti-TNF failure in psoriasis [PDF]

, 2013
An association among the occurrence of antidrug antibodies (ADAs), diminished trough serum drug levels (TSDLs) and non-response or loss of response has been described for several tumor necrosis factor alpha (TNF) blocking agents in a variety of diseases,
BRACKE, STEFANIE, Lambert, Jo
core   +1 more source

Efficacy of Adalimumab for Nail Psoriasis During 24 Months of Continuous Therapy

Acta Dermato-Venereologica, 2020
Psoriatic nail symptoms are frequent in psoriasis, affecting up to 80% of patients. Therapy responses to nail symptoms are often limited. In this multicentre non-interventional prospective study, 267 patients with nail involvement were treated with ...
Georgios Kokolakis, Frank Bachmann, Kerstin Wolk, Robert Sabat, Sandra Philipp   +4 more
doaj   +1 more source

Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review

American Journal of Clinical Dermatology, 2022
The decision of when to discontinue systemic treatment after achieving remission in psoriasis is an important question. In this systematic review, we sought to evaluate time to relapse after the discontinuation of systemic treatment in psoriasis patients.
M. Masson Regnault, J. Shourick, F. Jendoubi, M. Tauber, Carle Paul   +4 more
semanticscholar   +1 more source

Secukinumab in the treatment of psoriasis: patient selection and perspectives. [PDF]

, 2018
Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Beck, Kristen M, Liao, Wilson, Yang, Eric J   +2 more
core   +1 more source